Novavax Scheduled to Report Q3 2026 Earnings on November 5
Novavax (NVAX) is set to release its third-quarter 2026 financial results on Thursday, November 5, prior to the market opening. The company's performance will be measured against a consensus earnings per share (EPS) estimate of -$0.42, which represents a significant year-over-year improvement of 66.4%. Revenue expectations for the quarter are projected at $50.42 million, marking a forecasted decline of 28.4% compared to the same period last year. Investors will be closely monitoring these results to gauge the company's current trajectory and fiscal stability following recent shifts in earnings estimates.
Tickers: $NVAX